Current News

Walbrook PR announces its appointment as Financial PR advisor to AIM listed healthcare company Avacta Group plc (AIM: AVCT). Walbrook now acts for 14 AIM listed healthcare companies and is ranked No.1 for Healthcare in the AIM Advisers Rankings Guide.

Avacta Group plc is a provider of diagnostic tools, consumables and reagents used in human and animal healthcare, and operates through three key business areas:

Avacta Analytical – instrumentation to reduce the cost and risk of drug development

Avacta Animal Health – veterinary diagnostics products and services

Avacta Life Sciences – reagents and tools for life sciences, driven by a proprietary alternative to antibodies

Most recently, they launched Sensipod™ to veterinary practices in the UK along with the first point of care test to screen dogs for environmental allergies. Sensipod is an in-clinic diagnostic system designed to detect a wide range of markers of disease by rapidly carrying out an enzyme linked immunosorbent assay (ELISA) test - the gold standard for diagnostic tests - on a small sample of blood.

Avacta raised £4.7m gross in August 2013 to strengthen the balance sheet and support the Company's future development. They will announce Preliminary Results for the year ended 31 July 2013 on Thursday 24 October 2013. Walbrook will advise Avacta Group on its communications with the financial media, research analysts and other Small Cap and AIM investors. For more information, please visit: http://www.avacta.com

Paul McManus, Director of Walbrook PR, said: "We are very pleased to be working with Avacta at such an exciting stage of the business. They are well funded for future growth, sales of Optim2 are accelerating, Sensipod has been launched for the vet market, and the reagents and microarray business is on track to deliver revenues in 2014. Walbrook has built up a very strong position in the Life Sciences space, which combines well with our passion for working growing businesses, securing our position as the No. 1 Financial PR agency for AIM listed healthcare stocks."